SUMMARY Phenylacetic acid, p-hydroxyphenylacetic acid, m-hydroxyphenylacetic acid, phenylalanine, indoleacetic acid, 5-hydroxyindoleacetic acid and tryptophan were measured in lumbar and cisternal cerebrospinal fluid (CSF) taken during pneumoencephalography. The data suggest that the concentration of the acid metabolites of the trace amines tryptamine, phenylethylamine, p-tyramine and m-tyramine in lumbar CSF are influenced by the system that transports these acids out of CSF. In cistemal CSF this mechanism does not operate and more information can be obtained on the metabolism of the parent amines in the CNS. Our data indicate that (1) m-tyramine is relatively unimportant quantitatively (2) the rate of metabolism of phenylethylamine in human brain is similar to that of 5-hydroxytryptamine (3) the most important variable controlling the synthesis of phenylethylamine is the activity of aromatic amino acid decarboxylase (4)p-tyramine is synthesised at about half the rate of phenylethylamine and is thus quantitatively important in metabolic terms.
Studies on the metabolism of monoamines in the human CNS through measurement of amine metabolites in the cerebrospinal fluid (CSF) have concentrated on the catecholamines and 5-hydroxytryptamine (5HT). However, with increasing interest in the possible functions of the trace amines in the CNS, some studies have reported on trace amine metabolites in human CSF. Thus, the metabolite of tryptamine, indoleacetic acid (IAA), is present in CSF at a concentration which is positively correlated with that of CSF tryptophan.' This, and the fact that tryptophan administration increases CSF IAA in proportion to the size of the tryptophan load,2 indicates that human CNS tryptamine metabolism is controlled in part by tryptophan availability. Another trace amine that is formed, like tryptamine, by the action of aromatic amino acid decarboxylase on an aromatic amino acid (in this case, phenylalanine) is phenylethylamine. Its acidic metabolite phenylacetic acid (PA) is present in CSF at a concentration that is of the same order of magnitude as the catecholamine metabolites; it may be elevated in schizophrenia3 and low in depression. 4 Of the other trace amines, the acidic metabolites of p-tyramine and p-octopamine are present in human ventricular and lumbar CSF.5 Their concentrations in lumbar CSF increase on administration of probenecid,6 indicating active CNS metabolism. This summarises most of what is known about trace amine metabolites in human CSF. In the present study we have measured IAA, PA, p-hydroxyphenylacetic acid (PHPA), a metabolite of p-tyramine, and m-hydroxyphenylacetic acid (MHPA), a metabolite of m-tyramine, as well as the amino acid precursors of those compounds, tryptophan and phenylalanine, in a series of CSF samples taken during diagnostic pneumoencephalography. This was done to provide more information on the metabolism of trace amines in human CNS and some of the factors that might influence it.
Methods
The study, performed on patients undergoing diagnostic pneumoencephalography (PEG) at the Montreal Neurological Hospital, was approved by the ethics committees of the Montreal Neurological Hospital and the Department of Psychiatry, McGill University. Some of the samples came from a previous study in which the patients received a tryptophan load before the PEG.2 The procedure was done on the fasting patients, without premedication, between 9.00 a.m. and 12 noon. The first 2 ml of CSF was used for routine diagnostic purposes and the next 2 to 6 ml were collected for analysis of indoles. This sample was derived from the lumbar sac, which in humans has a volume of about 15 m17 and will be referred to in this study as lumbar CSF. Oxygen was then injected until the lateral ventricles contained oxygen. Some CSF from this compartment was thus displaced down into the basal cisterns, and when most of the oxygen had been injected (average of 60 ml) a second sample of CSF (6 to 8 ml) was collected through the lumbar needle. This last sample consisted mainly of fluid that was originally in the basal cisterns and was displaced into the lumbar sac. It is referred to in this study as cistemal CSF. This conclusion was arrived at by comparing, using a two-tailed Student's t test, the concentration of these compounds in the CSF of the 23 patients who received no tryptophan load, with their concentration in the CSF of the patients who received tryptophan loads. This comparison was done five ways, using each of the four groups in table 1 and also taking the 11 patients whose CSF tryptophan was greater than 1000 ng/ml. The mean lumbar CSF tryptophan for this latter group was 2303 ng/ml, 7-4-fold higher than the mean of 311 ng/ml for the 23 patients who did not receive tryptophan. When phenylalanine, PA, PHPA and MHPA concentrations in the CSF of patients not given tryptophan were compared with their concentrations in each of these five tryptophan-treated groups, none of the differences were found to be statistically significant. Thus, as tryptophan administration affected only tryptophan, 5HIAA and IAA, in analysing the results data from all 39 patients were pooled when the calculations did not PHPA is probably derived from p-tyramine. The role of m and p -tyramine as precursors of MHPA and PHPA is also suggested by the distribution of the acids in rat brain which parallels that of m and p-tyramine.8 Transamination of phenylalanine is a minor pathway and the keto-acid that is formed can be reduced to phenylacetic acid or oxidised to o-hydroxyphenylacetate. '4 Thus, for all three acids the relevant amine is probably the main precursor of the acids measured in this study. The evidence also indicates that the acids in CSF come from the CNS and not the periphery. Thus, in cats 14C-phenylacetic acid penetrates the blood-CSF barrier only with difficulty,'5 and the hydroxy derivatives, which are more polar, would do so even less easily. If a compound diffuses from blood to CSF its concentration should be similar in different CSF compartments. Thus, we have suggested that the presence of a gradient within the CSF is strong evidence that a compound is derived from the CNS and not the periphery.'3 The presence of a gradient for 5HIAA, with higher levels in cisternal CSF than in the lumbar compartment (table 2) , has been known for many years.'6 We have seen a gradient for IAA in previous studies,' '3 but not in the present one (table  2) . This difference may be due to the fact that some of the patients in the present study received a tryptophan load. The cistemal-lumbar gradient we found for PHPA is consistent with the ventricularlumbar gradient reported previously,5 and indicates that PHPA is definitely of central origin. The absence of a gradient for PA and MHPA does not, of course, indicate perpheral origin, but may reflect active metabolism of the parent amines, phenylethylamine and m-tyramine, in the spinal cord.
The inverse gradient for phenylalanine, with higher levels in lumbar than in cistemal CSF (table  2) is a surprising finding. It may reflect the fact that phenylalanine is converted to tyrosine more readily in the brain than in the spinal cord, thereby partially depleting phenylalanine in the CSF compartments adjacent to the brain. Although tryptophan and phenylalanine compete wlth one another for the same transport system, the rise of plasma tryptophan after a tryptophan load was not large enough to lower CSF phenylalanine, in this study, or CSF tryosine in a previous report."
METABOLISM OF THE MONOAMINES IN THE HUMAN CNS
The levels of PA we found in the CSF are high for the metabolite of a compound, phenylethylamine, that is found in brain at very low levels. Specifically the level in lumbar CSF of epileptics on anticonvulsants (18*1 ng/ml, table 4) is similar to the 5HIAA levels we found in the same type of patients.' Two other studies have reported PA concentrations of 16.93 and 28-74 ng/ml in the lumbar CSF of control patients. Thus, the values, although variable, do seem to be as high as those of the biogenic amine metabolites. This indicates that in the human CNS the rate of metabolism of phenylethylamine is as great as the rate of metabolism of 5HT, a conclusion that has already been made for the metabolism of phenylethylamine in rat brain.'8
The concentration of PHPA we found in the lumbar CSF of treated epileptics (10-6 ng/ml, Phenylethylamine and tryptamine share not only the enzymes involved in their metabolism but also an ability to diffuse across the blood-brain barrier. 13 26 Thus, it may be variability in the decarboxylation of the precursor amino acids in peripheral tissues as much as in brain that causes the wide range of concentrations of PA and IAA in CSF.
The only other correlation we found was a negative relationship between phenylalanine and MHPA which was seen only in cisternal CSF and thus, if it is real, probably reflects a metabolic relationship. However, we are not able to provide any explanation or interpretation of this finding.
Our data indicate that phenylethylamine is metabolised in human brain at a rate that is similar to that of the biogenic amines. This, and the fact that it has structural and behavioural similarities with amphetamine,27 point to a need for further information about the role of this amine in human CNS. p-Tyramine is metabolised at a rate about half that of phenylethylamine and also deserves further study. Because the concentration of the acid metabolites of the trace amines in lumbar CSF seems to be influenced by the transport of these compounds out of CSF, further studies on these compounds would be best performed on cisternal CSF (which can be obtained during pneumoencephalography) or on lumbar CSF after administration of probenecid. 
